Development in the syllabus of Pharmaceutical Marketing & Management that is studied in the Bachelor of Pharmacy course of Bangladeshi Universities.        LOSECTIL stands beside acid survivors        Vitamin D Levels Linked to Parkinson's Symptoms        Keeping the newborn warm at home at winter        Its time to prevent cervical cancer        Huge Rise in CT, MRI, Ultrasound Scan Use: Study        Exercise May Delay Early Aging of People With Diabetes        Alzheimer's Drug Shows Some Promise in Trials        Obesity, Depression Blamed for Daytime Sleepiness Epidemic        Fruits, Veggies May Help Smokers Quit     

Member Sign In
Forgot Your
Username & Password?


Not a Member?
Please Sign Up Here


 
 
Sr. Executive / Executive, Production; THE IBN SINA PHARMACEUTICAL IND LTD

 
Approval of Edurant Tablets (rilpivirine) by FDA
Brand Name: Edurant Tablets
Generic Name: rilpivirine
Company Name: Tibotec Pharmaceuticals
Date of Approval: May 20, 2011
Treatmant for: HIV Infection
The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-nave).

Edurant belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitor (NNRTI). The drug works by blocking HIV viral replication. Edurant is to be used as part of a highly active antiretroviral therapy (HAART) regimen that is designed to suppress the amount of HIV (viral load) in the blood. Edurant is a pill taken once a day with food.

Patients may respond differently to various HIV drugs or experience varied side effects. FDAs approval of Edurant provides an additional treatment option for patients who are starting HIV therapy, said Edward Cox, M.D., M.P.H, director, Office of Antimicrobial Products in the FDAs Center for Drug Evaluation and Research.

The safety and effectiveness of Edurant is based on 48-week data from two Phase 3 clinical trials with 1,368 adult subjects with HIV infection, and from a 96-week (with extension to 192 weeks) trial. Patients had not received prior HIV therapy and were selected to receive treatment with Edurant or efavirenz (another FDA-approved NNRTI for the treatment of HIV infection). Both drugs were given in combination with other antiretroviral drugs.

Edurant was as effective as efavirenz in lowering viral load. In the Edurant and efavirenz groups, 83 percent and 80 percent of subjects, respectively, had undetectable amounts of HIV in their blood after 48 weeks of treatment. Patients receiving Edurant who had a higher viral load at the start of therapy were more likely not to respond to the drug than were patients with a lower viral load at the start of therapy. In addition, persons who failed therapy with Edurant developed more drug resistance than patients who failed efavirenz.

The most commonly reported side effects in patients taking Edurant included depression, difficulty sleeping (insomnia), headache and rash. Fewer patients stopped taking the drug due to side effects as compared to patients taking efavirenz.

Edurant does not cure HIV infection. Patients must stay on continuous HIV therapy to control HIV infection and decrease HIV-related illnesses.

Edurant is manufactured by Raritan, N.J-based Tibotec Therapeutics, a division of Centocor Ortho Biotech Inc.
Note: To know more please go to the following sources.
Update: 2011-05-20
Source: Drugs.com & FDA
 
Other FDA Approval
Approval of Juvisync Tablets (simvastatin and sitagliptin) by FDA
Approval of Ferriprox (deferiprone) by FDA
Approval of Sylatron (peginterferon alfa-2b) by FDA
Approval of Gadavist Injection (gadobutrol) by FDA
Approval of Erwinaze (asparaginase Erwinia chrysanthemi) by FDA
Approval of Onfi (clobazam) by FDA
Approval of Benlysta Injection (belimumab) by FDA
Approval of Lazanda Nasal Spray (fentanyl) by FDA
See all the FDA Approval